Business Daily from THE HINDU group of publications Wednesday, May 16, 2007 ePaper |
|
|
|
|
|
|
|
Corporate
-
Overseas Investments Marketing - Strategy Natco expanding retail presence in US G. Naga Sridhar
Hyderabad May 15 As a part of its strategy to foray into the US market, Natco Pharma Ltd is expanding its retail presence in the US and will be acquiring two standalone pharma stores soon. The Hyderabad-based, mid-sized pharma company is in an advanced stage of talks to acquire two stores located in Pennsylvania and New Jersey. "The acquisition will be completed by next month," Mr P. Bhaskara Narayana, Director and Chief Financial Officer, Natco, told Business Line here. The company is currently running a store in New Jersey, which it acquired about nine months ago with sales of $1.5 million per month. With the addition of two more stores, its retail pharma sales in the US would go up to over $30 million per annum. "We are selling products of all major companies, including Indian pharma majors such as Ranbaxy and Dr Reddy's now and expect to sell Natco's own products by 2009," Mr Narayana said. Asked about replicating the model in the domestic market, Mr Narayana said they did not have any plans now. Also the realty prices were so high in major Indian cities, that it was uneconomical. In fact, the prices were more competitive in some US cities.
Three new products
On the product front, the firm has lined up three new products for release in the next month, including two in the oncology segment. Further, it is conducting toxicology studies on two new chemical entities for treatment of blood cancer. "We are expecting them to be ready by December this year. They will be blockbusters," he added. Besides, work on various analogues useful in the field of anti-cancer, anti-depressant and anti-ulcer therapies and on development of molecules based on new drug delivery systems was in progress. The company had so far filed three abbreviated new drug applications and was working on others.
More Stories on : Overseas Investments | Strategy | Pharmaceuticals
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2007, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|